Form 4: Voyager CFO Sells Shares for Tax Obligations

Voyager Therapeutics' CFO, Nathan D. Jorgensen, sold 4,668 shares of common stock at a weighted average price of $3.77 to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Chief Financial Officer Nathan D. Jorgensen of Voyager Therapeutics, Inc. (VYGR) sold 4,668 shares of the company's common stock.
• The transaction occurred on February 24, 2026, at a weighted average price of $3.77 per share, with individual sales ranging from $3.61 to $3.86.
• This sale was a 'sell-to-cover' election to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 21, 2026.
• The sale was executed pursuant to a durable automatic sale instruction (Rule 10b5-1(c) plan) adopted by Jorgensen on May 9, 2025, and was not a discretionary trade.
• Following this transaction, Nathan D. Jorgensen beneficially owns 151,416 shares of Voyager Therapeutics common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale is a non-discretionary transaction for tax purposes related to equity compensation, rather than an indication of management's sentiment about the company's future.

Positives

• The sale was non-discretionary, executed under a pre-arranged 10b5-1 plan, indicating a planned transaction rather than a reaction to new information.
• The transaction is related to the vesting of restricted stock units, which represents compensation for the CFO.

Negatives

• The CFO sold 4,668 shares of common stock, reducing his direct holdings in the company.

Future Outlook

NA

Management Comments

• The sales do not represent a discretionary trade by the reporting person.

Industry Context

StockSavvy.ai notes that sell-to-cover transactions are common practice for executives to manage tax liabilities associated with equity compensation, and typically do not signal a change in management's outlook on the company's prospects.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor dilution from the sale, but the transaction is routine and not indicative of a change in company fundamentals.

Next Steps

• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the reported range upon request.

Key Dates

Recommendation

The transaction is a routine 'sell-to-cover' for tax purposes, executed under a pre-arranged 10b5-1 plan. It does not reflect a discretionary decision by the CFO based on new information about the company's prospects. Therefore, it provides no new fundamental information to warrant a change in investment recommendation, suggesting a 'hold' position is appropriate unless other factors are considered.

Keywords

Voyager Therapeutics, VYGR, Form 4, Insider Trading, Stock Sale, CFO, Nathan Jorgensen, Restricted Stock Units, Tax Withholding, 10b5-1 Plan